On this page you will find useful information regarding which patients should be initiated on UPTRAVI®, guidance on prescribing and administering UPTRAVI®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension (WSPH) proceedings, and recommendations for screening and diagnosing patients with systemic sclerosis (SSc) or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Prescribing UPTRAVI®
Access the UPTRAVI® SmPC and patient information leaflet.
PAH guidelines and organisations
Continue reading
Discover how UPTRAVI® can provide long-term benefits for patients with PAH.[1]
UPTRAVI® has a predictable and manageable safety profile.[1][2]
Adding UPTRAVI® is recommended for patients not fully at low risk with ERA + PDE-5i.[3][4]
CHD, congenital heart disease; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; FC, functional class; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; PDE-5i, phosphodiesterase type 5 inhibitor; SSc, systemic sclerosis; WHO, World Health Organization; WSPH, World Symposium on Pulmonary Hypertension
UPTRAVI® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING
